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Digital intervention increases influenza vaccination rates for
people with diabetes in a decentralized randomized trial
J. L. Lee 1,2, L. Foschini 1, S. Kumar1, J. Juusola1, J. Liska3, M. Mercer4, C. Tai1, R. Buzzetti5, M. Clement6, X. Cos7,8, L. Ji9, N. Kanumilli10,
D. Kerr 11, E. Montanya 12, D. Müller-Wieland13, C. G. Ostenson14, N. Skolnik15, V. Woo16, N. Burlet17,18, M. Greenberg4 and
S. I. Samson 19✉
People with diabetes (PWD) have an increased risk of developing influenza-related complications, including pneumonia, abnormal
glycemic events, and hospitalization. Annual influenza vaccination is recommended for PWD, but vaccination rates are suboptimal.
The study aimed to increase influenza vaccination rate in people with self-reported diabetes. This study was a prospective, 1:1
randomized controlled trial of a 6-month Digital Diabetes Intervention in U.S. adults with diabetes. The intervention group received
monthly messages through an online health platform. The control group received no intervention. Difference in self-reported
vaccination rates was tested using multivariable logistic regression controlling for demographics and comorbidities. The study was
registered at clinicaltrials.gov: NCT03870997. A total of 10,429 participants reported influenza vaccination status (5158 intervention,
mean age (±SD)= 46.8 (11.1), 78.5% female; 5271 control, Mean age (±SD)= 46.7 (11.2), 79.4% female). After a 6-month
intervention, 64.2% of the intervention arm reported influenza vaccination, vers us 61.1% in the control arm (diff= 3.1, RR= 1.05,
95% CI [1.02, 1.08], p= 0.0013, number needed to treat= 33 to obtain 1 additional vaccination). Completion of one or more
intervention messages was associated with up to an 8% increase in vaccination rate (OR 1.27, 95% CI [1.17, 1.38], p < 0.0001). The
intervention improved influenza vaccination rates in PWD, suggesting that leveraging new technology to deliver knowledge
and information can improve influenza vaccination rates in high-risk populations to reduce public health burden of influenza.
Rapid cycle innovation could maximize the effects of these digital interventions in the future with other populations and vaccines.
npj Digital Medicine           (2021) 4:138 ; https://doi.org/10.1038/s41746-021-00508-2
INTRODUCTION
Seasonal influenza is associated with approximately 290,000–640,000
deaths worldwide each season1, and impacts approximately 21
million people in the United States annually, resulting in significant
public health and economic burdens2. Preventing viral illnesses such
as influenza is truly a global concern, given the potential for
transmission in a modern, global culture, with this global risk and
impact having been emphasized by the ongoing COVID-19
pandemic. People with diabetes (PWD), face increased risks from
influenza, including poor glycemic control, pneumonia, premature
death, acute cardiovascular complications, and hospitalizations3–5
which may result in a significant burden to the personal costs of
healthcare for PWD. Vaccination remains the most effective primary
prevention method against influenza, with effectiveness ranging
from 29 to 48%6,7. Vaccination for influenza in PWD is effective in
reducing the risk of hospitalizations and mortality3,8, as well as the
overall cost of hospitalizations3,7. Influenza vaccination has also been
shown to be safe for PWD and does not impact an individual’s ability
to engage in daily activities in the days following vaccination5,7,9.
However, vaccination rates remain suboptimal, consistently falling
under the 70% vaccination rate goal set by national guidelines
for all individuals in the United States10. In 2015 in the United
States, 61.6% of adults with diabetes received an influenza vaccine11.
During 2016–17, national rates of influenza vaccination were
approximately 40% in adults without any high risk conditions,
and 59.7% for adults with a variety of high risk conditions (including
diabetes)12.
Therefore there is a need for effective and scalable solutions to
increase influenza vaccination rates in PWD. While a number of
randomized controlled trials (RCTs) have assessed the effective-
ness of interventions for increasing influenza vaccination rates,
many have focused on other age groups or populations13. One
prospective digital interventional study demonstrated the poten-
tial effectiveness of general messaging and incentives via a health-
related smartphone application (app) to increase vaccine uptake
in a general Canadian population14, suggesting this kind of
intervention could be effective in PWD. A large RCT using digital
messaging was also effective in increasing vaccination rates in the
general population of adults in the United States15. The use of
health information technology (e.g., searching the internet for
health information, emailing providers) and even simple electronic
reminders delivered via digital patient portals have resulted in
increased influenza vaccination rates, suggesting the potential of
simple digital solutions16,17. One of the primary reasons PWD
report not getting vaccinated is a belief that they are not in a high-
risk group, and providing education on the increased risk of
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negative health outcomes following influenza infection has shown
promise in increasing vaccination rates in other populations18.
Additional reasons include fear of adverse reactions, difficulties
with accessing the vaccine (e.g., time, health center access), or
other beliefs surrounding the influenza vaccine (e.g., not effective,
transmits the flu)19. Therefore, digital messaging that counters this
lack of knowledge and barriers to vaccination could be effective
for increasing uptake.
The aim of this study was to evaluate the effectiveness of a
digitally administered intervention to increase influenza vaccine
rates for PWD using a decentralized, blinded RCT. The primary
endpoint was to examine the difference in self-reported influenza
vaccination rates in 2 groups: PWD who received a digital
intervention (PWD-I) and PWD who received no intervention
(PWD-C). The following exploratory associations were also
examined: (a) the impact of engagement with interventions on
the influenza vaccination; (b) the impact of the timing of the
intervention messages during influenza season on influenza
vaccination status; (c) the reported level of influence on getting
the influenza vaccine by each intervention message type within
the PWD-I group; (d) the level of engagement with each
intervention message within the PWD-I group; and (e) the impact




The study was launched in September of 2018 and the last
participant completed the final survey in April of 2019, with the
intent to capture outcomes during the 2018–2019 influenza
season in the United States. A CONSORT diagram is included (Fig.
1) as a description of the larger investigation, including informa-
tion on the 3 cohorts. For the PWD cohort, a total of 31,404
individuals were randomized, resulting in 15,702 in the PWD-I
group and 15,702 in the PWD-C group. The PWD-I group consisted
of 5158 individuals who completed the mid-study or final survey
reporting their influenza vaccination status, and 5271 in the PWD-
C group who reported their influenza vaccination status over the
same interval. Approximately one-third of participants who were
enrolled and randomized reported on the final endpoint. Figure 2
shows the flow of participants through the study, timing of the
surveys, and timing of the intervention messages.
Descriptive characteristics for the sample are presented in Table
1. Demographic variables of age, race/ethnicity, and sex were not
Fig. 1 CONSORT flow diagram. CONSORT diagram presents the study flow for the larger investigation (NCT03870997). PWD people with
diabetes, NC-S normal controls-similar, NC normal controls.
Fig. 2 Study flow and intervention delivery. Depicts the study flow for participants and the timing of the intervention messages. The timing
of the surveys and the corresponding n participants who completed those surveys is also included. PWD-I People with diabetes-intervention
group, PWD-C People with diabetes-control group.
J.L. Lee et al.
2













different between the two groups, indicating that randomization
was successful. The participants were predominantly female,
White, and in the middle age range and had high levels of income
and education. Hypertension, depression, and high cholesterol
were the most commonly reported comorbidities, with a small
proportion reporting coronary artery disease. Participants included
individuals from 48 of the United States, as well as the District of
Columbia, United States Armed Forces, and Guam. A total of 101
individuals reported discrepant answers at the 3-month and
6-month questionnaires with regard to vaccination status. The
effect size remained unchanged and statistically significant after
re-running the primary outcome without these individuals.
Primary endpoint
With regards to the primary outcome, 3310 (64.2%) of 5158
participants from PWD-I reported flu vaccination, compared with
3220 (61.1%) of 5271 among the PWD-C participants, with an
absolute intervention difference of 3.1%. The number needed to
treat or message for this effect is 33 people to result in 1
additional influenza vaccination. After adjusting for age, sex, race,
and comorbidities, the intervention group was more likely (RR
1.05, 95% CI [1.02, 1.08], p= 0·0013) to get flu vaccination than the
control group.
Exploratory outcomes
Greater rates of engagement measured by larger number of
interventions completed was associated with an increased
Table 1. Participant demographics.
Sample that reported on primary endpoint of vaccination status






Mean (SD) Mean (SD)
46.8 (11.1) 46.7 (11.2)
n (%) n (%)
Sex Female 4048 (78.5) 4183 (79.4)
Male 1096 (21.2) 1066 (20.2)
Other 14 (0.3) 22 (0.4)
Race/ethnicity African American/
Black
468 (9.1) 451 (8.6)
American Indian or
Alaska Native
50 (1.0) 53 (1.0)
Asian 163 (3.2) 169 (3.2)
Caucasian/White 3990 (77.4) 4141 (78.6)
Native Hawaiian or
other Pacific Islander
19 (0.4) 18 (0.3)
Other 137 (2.7) 134 (2.5)
Multiracial 331 (6.4) 305 (5.8)
Ethnicity Hispanic/Latinx 496 (9.6) 519 (9.8)
Not Hispanic/Latinx 4662 (90.4) 4752 (90.2)







n (%) n (%)
Income Less than $25,000 409 (12.1) 376 (11.0)
$25,000–$34,999 343 (10.1) 381 (11.1)
$35,000–$49,999 480 (14.2) 485 (14.2)
$50,000–$74,999 679 (20.1) 729 (21.3)
$75,000–$99,999 504 (14.9) 493 (14.4)
$100,000–$149,999 439 (13.0) 437 (12.8)
$150,000 or more 195 (5.8) 174 (5.1)
I prefer not
to answer
335 (9.9) 352 (10.3)
Education Did not complete
high school, no
diploma
42 (1.2) 38 (1.1)
Trade/technical/
vocational training




347 (10.3) 399 (11.6)
Some college,
no degree
779 (23.0) 795 (23.2)
College graduate 1364 (40.3) 1328 (38.8)
Graduate degree 504 (14.9) 517 (15.1)
Doctorate degree 72 (2.1) 80 (2.3)
I prefer not
to answer
18 (0.5) 19 (0.6)
Medical
comorbidities
Cancer 329 (6.4) 335 (6.4)
Chronic heart failure 56 (1.1) 57 (1.1)
Coronary artery
disease
97 (1.9) 112 (2.1)
Depression 1988 (38.5) 2038 (38.7)
High blood pressure 2318 (44.9) 2307 (43.8)
High cholesterol 1914 (37.1) 1883 (35.7)
Table 1 continued
Sample that reported on primary endpoint of vaccination status






Mean (SD) Mean (SD)
46.8 (11.1) 46.7 (11.2)




33.3 (8.1) 33.3 (8.1)
Note. For BMI, 5 individuals in each cohort provided insufficient data to
calculate BMI and are thus not included in analysis.
Fig. 3 Vaccination rate per completed interventions for people
with diabetes in the intervention group. Depicts the influenza
vaccination rate for the PWD-I People with diabetes-intervention
group, based upon the number of the intervention messages that
were completed during the intervention period with standard error.
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vaccination rate for PWD-I (Fig. 3). Participants in the PWD-I arm
who completed at least one digital intervention were more likely
to report influenza vaccination (PWD-I: 66.6%; PWD-C: 61.1%, OR
1.27 95% CI [1.17, 1.38], p < 0·0001) than PWD-C. Participants in
PWD-I who responded to at least 3 messages had an even greater
odds of reporting influenza vaccinations (PWD-I: 69.0%; PWD-C:
61.1%, OR 1.42, 95% CI [1.30, 1.56], p < 0·0001) than PWD-C. Of
note, within PWD-I, participants who did not complete any
messaging interventions were less likely to report influenza
vaccination (OR 0.61, 95% CI [0.52, 0.72]) than those who
completed interventions.
The impact of timing of the intervention messages during
influenza season on influenza vaccination rates within the PWD-I
group, compared to the passage of time in the PWD-C group, is
shown in the Kaplan–Meir curves in Fig. 4. Participants were asked
to score the level of influence each message had on their decision
to vaccinate (Fig. 5). Participants within PWD-I did not report
differences in the effect of the messaging itself on the decision to
vaccinate. Participants reported a mean score ranging between
2.75 to 2.93 for each of the messages. Figure 6 presents the
response rates (i.e., number of responses per 100 persons) for each
of the 6 different interventions. Each intervention message had a
pattern of similar rates of clicks and completions with a much
smaller rate of dismissals. Participants were most likely to respond
to the first two messages with an overall decline in response rates
in later months. Advice given by a healthcare worker to vaccinate
had a strong effect on the decision to vaccinate among both
control and intervention groups (OR 12.3, 95% CI [10.2, 15]).
Participants who reported specific counseling to get influenza
vaccination were slightly older than those who did not (44.9 vs
46.7 yrs., OR 1.01, 95% CI [1.01, 1.02], p value <0.001), more likely
to have a self-reported cholesterol disorder (33.3 vs 45.1%, OR 1.18
95% CI [1.05, 1.32], p value <0.01).
DISCUSSION
This RCT used a digital intervention to significantly increase
influenza vaccination rates in a large sample of PWD, reaching the
primary endpoint with an increase of 3.1%. Influenza vaccination
rates in the control group were consistent with those most
recently published at a national population level for PWD11.
Greater rates of engagement with a larger number of interven-
tions were associated with increased vaccination rate, up to 8% for
at least 1 or more intervention messages completed compared to
the control group. Engagement rates with the intervention were
overall high, with completion rates between 17 and 25% across
intervention messages, consistent with digital communication
industry standards20. The increase in vaccination rate seen in this
study is much higher than that previously seen in other general
digital interventions for increasing influenza vaccination rates15; it
was, however, smaller than that was seen in a prospective
interventional study (5% increase) that provided compensation for
vaccination14. Although compensation was provided for comple-
tion of the interventions, the total compensation was only $0.30
per participant, suggesting that this was not a motivating factor
for completing the intervention. The Kaplan–Meier curves
demonstrate that from the start of the influenza season in 2018,
the steepest rates of influenza vaccination took place in the first
two months, with individuals in the PWD-I group being more likely
to vaccinate earlier in the influenza season. Divergence between
the two groups appeared to occur shortly after the first two
months, with the PWD-I group continuing to experience more
vaccinations until the fourth month, when both groups started to
plateau. Given that the vaccination rates between the intervention
and control groups diverged during the later months, the
messages in months 3–6 might have had a greater impact on
vaccination rates at an earlier date in the flu season. Although not
statistically significant in difference, the two messages rated as
directionally most influential for getting an influenza shot were in
October and November, which were messages that targeted
information on “The Flu and Diabetes” and centered around
“World Diabetes Day,” respectively, suggesting a synergy could be
possible between relevant disease-focused events and interven-
tion deployments. These also provided information that was very
specific to the diagnosis of diabetes and the impact of influenza.
Fig. 4 Time to vaccination in the PWD-I group compared to the
PWD-C group. Depicts the vaccination rate over the course of the
study using a Kaplan–Meier curve. PWD-I People with diabetes-
intervention group; PWD-C People with diabetes-Control group.
Fig. 5 Level of influence from messages on getting the influenza
vaccine. Depicts the ratings provided by the PWD-I: People with
diabetes-intervention group regarding how influential each mes-
sage was on their decision to get the influenza vaccine. Ratings
include standard error and were not statistically significantly
different between interventions.
Fig. 6 Different response types among PWD-I for each interven-
tion message. Depicts the levels of engagement and different
response rates for each intervention from the PWD-I: People with
diabetes-intervention group.
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Results also indicated that people who received the recommenda-
tion from a healthcare worker to get vaccinated were vaccinated
at greater rates, consistent with prior literature suggesting the
importance of the role of the healthcare provider in promoting
influenza vaccination19.
The analysis found that vaccination rates increased 3.1% in the
intervention group compared to controls, but the association of
completing the interventions with vaccination rate could be up to
8% for those who completed interventions. The CDC21 estimates
that there are 26.8 million individuals with diabetes living in the
US. An absolute increase of 3.1% in vaccination rate at a national
level could represent approximately 830,000 additional PWD in
the United States receiving the influenza vaccination. While there
are unique characteristics in the medical and insurance system in
the United States that present barriers to influenza vaccination
that may not be encountered in countries with universal
healthcare, suboptimal vaccination rates are a global concern,
and this intervention could have broader generalizability.
Strengths of the study include the large and diverse sample of
PWD, representing most of the geographic United States with
wide age and socioeconomic range. Additionally, a unique
strength of a web-based RCT is the ability to blind participants
not only to their treatment condition, but to their study
participation, providing the opportunity to test how individuals
would respond to the intervention in real-world settings. This
clinical trial also enrolled participants quickly with high geo-
graphic variability, a strength of this decentralized trial format and
consistent with other decentralized clinical trials22. As only
approximately 33% of the participants completed the mid-point
or final survey containing the primary endpoint, these results
could be an inaccurate estimate of the true effect of the
intervention given missing data. What remains true is that
participants who completed 50% or more of intervention
messages in the PWD-I cohort had an even higher vaccination
rate than those who did not, suggesting that the current results
could be an underestimate of the effect measured in this
population. While self-report of influenza vaccination has shown
good specificity in large populations, the most accurate estimate
of vaccination status would result from a combination of self-
report and medical claims data23,24. Future research should
consider this approach to reduce potential self-report bias.
The primary shortcoming of this study is the limited general-
izability of the study population which may not represent the
entire United States population with diabetes. The majority of
participants were female and of non-Hispanic white race/ethnicity.
They also represented an educated population, with most having
a college degree and above average income levels. It is also
possible that the Achievement population represents a more
digitally connected population, representative of those who seek
out digital health resources. While the initial results from
evaluating the Digital Diabetes Intervention are promising and
demonstrated an effect in this sample, these results are not easily
generalizable to a broader population of PWD. This study should
serve as a building block for future research. The intervention
content would benefit from further development and tailoring to
reach individuals from diverse backgrounds effectively. Brewer
and colleagues25 highlight the potential of mobile health
interventions for improving health outcomes in individuals from
diverse backgrounds, demonstrating that more individuals from
racial and ethnic minorities use mobile apps and smartphones to
access health information than white individuals and are generally
receptive to participating in digital health research. Digital
interventions have great potential for reducing health disparities
if barriers to health equity surrounding internet connectivity and
equitable access to hardware are reduced26. While delivered via
the Achievement app, the intervention messages within the
Digital Diabetes Intervention were built as individual webpages.
For dissemination, messages like these could also be sent using
hyperlinks via text or even as healthcare medical record portal
messages. The COVID-19 pandemic has demonstrated the
significant reach of digital health technologies, with increased
adoption of telehealth services during the pandemic around the
world25,27, highlighting the ability of individuals to adapt to
changing models of healthcare. Approximately 33–52% of PWD
use mobile apps to manage their health28, suggesting that a
digital intervention may be especially impactful for PWD, with the
increasing prevalence of app-connected continuous glucose
monitors and the use of technology for managing diabetes.
This study shows that a relatively low-cost digital intervention
using information from existing trusted sources is an effective way
to increase vaccination rates among individuals with diabetes.
Total compensation for the study, had all individuals completed all
of the interventions, would have been approximately $4700, and
recruitment leveraged an existing community of PWD, a general-
izable cost-effective recruitment strategy for connected patient-
focused or healthcare organizations. Digital interventions such as
this have wider public health implications. A single influenza
season costs the United States approximately $3.2 billion in
medical costs, $8.0 billion in indirect costs, and $11.2 billion in
overall economic burden2. There is also evidence that hospitaliza-
tion due to influenza is 78% lower in PWD who are vaccinated
than in PWD who are not vaccinated3, compared to a 58% lower
chance of hospitalization in vaccinated people without diabetes.
This suggests that high healthcare costs from hospitalization due
to influenza are likely to impact this high-risk population of PWD
disproportionately and could be reduced by vaccination. Further
analyses should be conducted to understand how to maximize
the cost-effectiveness of a digital intervention, compared to
traditional in-person interventions. It would also be beneficial to
evaluate efficacy of a digital intervention in increasing vaccination
rates for individuals with other high-risk conditions, such as
cardiovascular disease. As the world undergoes the most
extensive vaccination campaign in history for the COVID-19
vaccine, the effectiveness of interventions that address hesitancy
and misinformation surrounding vaccination is critical given the
already high levels of hesitancy and resistance to vaccination29,30.
This study supports that personalized and timely digital messages
could make a significant difference in the number of people who
get vaccinated. Although this intervention was developed with
the input of patients via focus groups and expert opinions, the
exact mechanisms of action for the intervention messages (i.e., the
active ingredients) are unknown. Future research should aim to
determine the mechanisms of action for digital interventions, as
well as the motivations for initial and sustained engagement in
the intervention. Obtaining this knowledge would help to
generalize and apply this intervention to other populations to




This decentralized RCT was conducted in the United States using the
Achievement platform, an online study platform with more than 3.5 million
members (myachievement.com, Evidation Health, Inc., San Mateo, CA) with
a research community of users ranging in age from 18 to over 90 years,
some with self-reported medical conditions. Achievement members can
connect their activity trackers, fitness, and health apps to the platform and
members accumulate points that are redeemable for monetary rewards for
completing tasks. This study is a part of a larger investigation into the
effectiveness of digital interventions for increasing vaccination rates,
registered at clinicaltrials.gov, posted 12 March, 2019 (NCT03870997). The
larger investigation consists of 3 cohorts, with 2 arms in each cohort (Fig. 1
—CONSORT diagram). The 3 cohorts in the larger investigation are: (a)
Individuals with self-reported diabetes (PWD cohort in white on Fig. 1), (b)
individuals without self-reported diabetes but who are otherwise similar to
PWD based on their demographic and activity tracker data (NC-S: normal
J.L. Lee et al.
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controls who are similar) and (c) individuals without self-reported diabetes
who are not in NC-S, but are similar to PWD with regards to age and
gender (NC: normal controls). The focus of this presentation is on the
particularly vulnerable population of PWD. Study design and sample size
calculations were based upon this cohort. The study was a 6-month RCT,
consisting of 2 arms: PWD who received the digital intervention (PWD-I)
and PWD who received no intervention, serving as a control (PWD-C).
Examples of the interventions are shown in the Supplementary Note 1.
Participants were blinded to study participation status, providing a
pragmatic trial design that has been advocated for in order to enhance the
generalizability and applicability of research conducted involving mobile
health technologies31. This study was approved by the ethical committee,
Solutions Institutional Review Board (IRB-Little Rock, AR) prior to any
participant engagement. It was determined that participants faced no
more than minimal risks from the study, as the intervention messages were
consistent with current standard of care, and a waiver of informed consent
was obtained from the IRB. Participants were informed that their survey
responses and behavioral data would be used for research purposes via a
Data Usage and Permissions Agreement at the beginning of each survey.
For inclusion in the study and allocation to the PWD cohort, participants
needed to be at least 18 years of age, have self-reported type 1 or type 2
diabetes designated in their Achievement health profile, and live in the United
States. For recruitment, a set of existing Achievement members who met the
inclusion criteria were tagged for study inclusion. This constituted the set of
study participants; they did not take any active steps to enroll in the study.
These study participants were sent offers to receive “points” as compensation
for completing surveys and study tasks, which is a routine component of
participating in the Achievement platform. Total compensation for completing
study surveys was the equivalent of $0.90, and total compensation for
interacting with the six monthly Diabetes Digital Interventions was the
equivalent of $0.30. Participants were randomized to the intervention (PWD-I)
or control (PWD-C) arm prior to receiving any study offers using stratified
randomization based upon sex and age as covariates with simple random
sampling based upon an a priori list of participants. Due to the web-based
nature of the study, blinding by investigator was not necessary as the
messages and study experience were determined prior to enrollment in the
trial, with the messages dispatched on predetermined dates without any
additional investigator interaction. Participants were blinded not only to their
intervention or control arm status, but also to the fact that they were enrolled
in a study, a factor that is unique to a web-based RCT. Due to the study design
and IRB determination that the study posed no more than minimal risk,
information on adverse events was not solicited and none were sponta-
neously reported.
Measures
Participants were sent an online baseline questionnaire, a mid-study
assessment at three months, and a final assessment at six months. Due to
the study design, participants could complete any or all assessments;
completion of mid-study and final assessment was not predicated on
completion of the baseline assessment. The primary endpoint of influenza
vaccination status was collected in the three- and/or six-month
questionnaires. Questions on demographics, influenza vaccination status,
and healthcare worker recommendation were asked of all participants.
Participants in the PWD-I cohort were additionally asked about their
perceptions of the interventions, and their engagement with intervention
tasks was assessed.
A demographic questionnaire was administered at baseline, three and six
months to all participants. Age, sex, and race/ethnicity were collected in all
three questionnaires. Participants were able to “select all” for race/ethnicity
and comorbidities. Information on medical comorbidities, income, and
education was collected only in the three- and six-month questionnaires.
For assessing influenza vaccination status, all participants were asked, “Did
you get vaccinated against the flu (sometimes called getting a flu shot) this
season? This year’s flu season began in September 2018,” and responded with
Yes/No. Self-reported influenza vaccination status has been shown to have
good specificity and positive predictive value23,24. Influenza vaccination status
was collected both at mid-study and end of study to minimize recall bias.
Participants were also asked for the approximate date on which they received
their influenza vaccine. All participants were asked in the final survey “Have
any of your healthcare providers recommended that you get a flu shot?” and
asked to indicate Yes/No. The PWD-I cohort was also asked about their
perceptions of the interventions and how much each message-type
influenced whether they got their flu shot, rating each message from 1
—“not influential at all” to 5—“very influential.” For each intervention,
engagement statistics were tracked for the PWD-I participants who (a) clicked
to open the digital intervention, (b) continued to complete the call to action
or (c) explicitly dismissed it.
Intervention content
Each of the six monthly messages was structured in two parts: educational
content, and a call to action for the participant to complete (Table 2).
Education and recommendations provided in the intervention were based
upon data from the United States Centers for Disease Control and
Prevention (CDC), World Health Organization (WHO), International
Diabetes Federation (IDF), and the American Diabetes Association (ADA),
thus reflecting the current standard of care recommendations for PWD.
Content was reviewed by an expert advisory board and focus group of
PWD. Messages were communicated via the Achievement app using
month-specific messages, for example occurring around World Diabetes
Day in November and National Heart Month in February. Calls to action
would award points to the participant for completing actions such as
needing to find the nearest clinic offering flu shots (CDC Flu Finder Widget)
or planning prompts32, which have been shown to be effective at
increasing influenza vaccination33. Incentives (via Achievement points)
were provided upon the completion of the call to action as described.
Sample size calculations and analytical plan
For sample size determination, we estimated a 2.7% increase in
vaccination rate between the PWD-I and PWD-C groups. This value was
selected to be consistent with prior research and clinically meaningful14,15.
Power analysis indicated the need for an analysis set of 4043 individuals in
each arm of the study (total N= 8086) to achieve 80% power to detect a
2.7% increase in vaccination rate with a type I error rate of 0.0534. To
account for potential non-response to study surveys, we tagged 31,404
Table 2. Description of intervention messages.
Month Educational message Call to action Goal of message
1 General influenza and vaccination facts8 Interactive quiz assessing knowledge Education
2 Unique risks of flu-related complications for PWD5,35 Commitment to receive vaccine on
selected date
Education, planning, and commitment
3 World Diabetes Day and information on flu-related
complications for PWD8
Agree to be emailed more information on
influenza vaccination
Education
4 Consequences of influenza, including decreased
activity and steps/points5
Put in zip code to find clinic near them using
vaccinefinder.org
Loss-aversion for points and location-
aware message
5 Safety of vaccination and common side effects36 Put in zip code to find clinic near them using
vaccinefinder.org
Decrease hesitancy and fear
6 Relationship between influenza and cardiac events
for PWD8,37
Pledge to get flu shot on specific date during
that month
Planning and commitment, education
Note. All intervention messages contained some information from publicly available materials from CDC, WHO, IDF, and ADA. Unique sources per-intervention
are referenced above.
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PWD for study inclusion, with 15,702 randomized to each of the two arms
(~25% assumed response rate).
Logistic regression models were used to compare self-reported vaccina-
tion rates in both study arms (PWD-I versus PWD-C) controlling for
demographics (i.e., age, sex, and race/ethnicity) and comorbid conditions,
to calculate the relative risk and absolute risk change using intent to treat
analyses. Per protocol analyses were used on all other analyses.
Kaplan–Meier plots were constructed to evaluate self-reported time-to-
vaccination for the two arms. Logistic regression models were constructed
to examine the effect of the number of completed interventions and
recommendations given by health care workers on vaccination rates,
controlling for demographics and comorbid conditions. Significance is
reported at a type I error rate of 0.05, with a type II error rate of 0.20.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
Qualified researchers may request access to the aggregate results and related study
documents including the study report, study protocol with any amendments, blank
case report form, statistical analysis plan, and dataset specifications. Further details
on Sanofi’s data sharing criteria, eligible studies, and process for requesting access
can be found at https://www.clinicalstudydatarequest.com.
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